Ginkgo Bioworks (DNA) vs Odyssey Therapeutics (ODTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Odyssey Therapeutics is the larger company by market cap ($870.8 million vs $763.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | ODTX |
|---|---|---|
| Share price | $11.34 | $18.12 |
| Market cap | $763.64M | $870.82M |
| 1-day change | -1.13% | +0.22% |
| YTD return | +36.46% | — |
| 1-year return | -29.52% | — |
| 5-year return | -97.62% | — |
| EPS (TTM) | $-5.06 | $-7.55 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $29.05 |
| 52-week low | $5.37 | $15.10 |
| Distance from 52-week high | -37.76% | -37.62% |
| Analyst consensus | none | none |
| Avg. price target upside | -38.27% | +97.30% |
| Average volume | 1.80M | 274.77K |
| Shares outstanding | 55.38M | 48.06M |
| Employees | 485 | 100 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- The two companies sit in different sectors: Ginkgo Bioworks in Healthcare and Odyssey Therapeutics in Health Care.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Healthcare · Biotechnology · 485 employees
About Odyssey Therapeutics
ODTX stock →Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptorassociated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 100 employees
DNA vs ODTX FAQ
Which is bigger, Ginkgo Bioworks or Odyssey Therapeutics?
Odyssey Therapeutics (ODTX) is larger, with a market capitalization of $870.82M compared with $763.64M for Ginkgo Bioworks (DNA).
Are Ginkgo Bioworks and Odyssey Therapeutics in the same industry?
No. Ginkgo Bioworks is in the Healthcare sector, while Odyssey Therapeutics is in Health Care.